Document is current

Article History

Received: 7 September 2025

Accepted: 30 November 2025

First Online: 7 January 2026

Declarations

:

: Speaker’s bureau: MB: Amgen, Adamed, Daiichi Sankyo, KRKA, MSD, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi, Teva, Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Lilly, MSD, New Amsterdam, Novartis, Novo-Nordisk, Sanofi, Teva; Grants from Amgen, Daiichi Sankyo, Viatris, Sanofi, and Teva. All other authors have no conflict of interest.

: Not applicable.

: Not applicable.

: Not applicable.

: All data generated or analysed during this study are included in this published article (and its supplementary information files).

: Not applicable.

: I.B. and S.E.: conceptualization, study design, methodology and project administration; I.B., S.B., D.G., M.S., E.D.: data analysis and writing the first draft of manuscript. M.B., M.Y.H., I.B., R.K., A.V.H., S.E.: review manuscript. I.B., M.B., A.V.H. revised the manuscript and prepared the final version. All authors have read and agreed to the final version of the manuscript.